SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.
Read more at prnewswire.comViracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
PR Newswire -
Tue Aug 16, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Palantir%20(PLTR)%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
